Progressive Supranuclear Palsy Market to Register Immense Growth by 2032 – DelveInsight | Key Companies – AlzProtect, TauRx Pharmaceuticals, Asceneuron, EmeraMed, UCB Biopharma, and Others

Delveinsight Business Research LLP
DelveInsight’s “Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Supranuclear Palsy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Progressive Supranuclear Palsy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Progressive Supranuclear Palsy: An Overview

Progressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech, and swallowing. The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low.

Although PSP is not fatal, symptoms do continue to worsen and it can not be cured. Complications that result from worsening symptoms, such as pneumonia (from breathing in food particles while choking during eating) can be life-threatening.

Progressive Supranuclear Palsy Market Key Facts

As per the study conducted by Viscidi et al. titled, “Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data”, the crude prevalence of PSP was 1.89 per 100,000 and age-standardized prevalence in the US population was 2.95 per 100,000. A little over half (53.5%) of patients were male.

The study titled “The prevalence of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) in the UK” by Nath et al. estimated that the prevalence of PSP in the UK was 1.0 per 100,000. The age-adjusted standardized prevalence figure for PSP from this study was observed to be 5.0.

The mean age at onset of PSP is approximately 63 years (44–75 years). The median interval between onset and diagnosis is 3 years (range, 0.5–9 years). PSP has a slight male predominance (Eggenberger et al., 2018). 

Progressive Supranuclear Palsy Market

Progressive Supranuclear Palsy Market Size is anticipated to increase during the study period owing to the increasing prevalent population of PSP patients in the 7MM. The launch of upcoming therapies will also boost market growth.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Progressive Supranuclear Palsy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Progressive Supranuclear Palsy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Progressive Supranuclear Palsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Progressive Supranuclear Palsy Epidemiology Segmentation – 

Total Prevalent cases

Gender-Specific Prevalent Cases 

Diagnosed and Treatable Cases

Type-Specific Prevalent Cases

Age-Specific Prevalent Cases

Progressive Supranuclear Palsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched during the study period. The analysis covers Progressive Supranuclear Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Progressive Supranuclear Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Progressive Supranuclear Palsy Therapeutics Analysis

Some of the key companies in the Progressive Supranuclear Palsy Market include:


UCB Biopharma

TauRx Pharmaceuticals

Asceneuron Therapeutics


And many others.

Progressive Supranuclear Palsy Therapies covered in the report include:





And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Progressive Supranuclear Palsy Competitive Intelligence Analysis

4. Progressive Supranuclear Palsy Market Overview at a Glance

5. Progressive Supranuclear Palsy Disease Background and Overview

6. Progressive Supranuclear Palsy Patient Journey

7. Progressive Supranuclear Palsy Epidemiology and Patient Population

8. Progressive Supranuclear Palsy Treatment Algorithm, Current Treatment, and Medical Practices

9. Progressive Supranuclear Palsy Unmet Needs

10. Key Endpoints of Progressive Supranuclear Palsy Treatment

11. Progressive Supranuclear Palsy Marketed Products

12. Progressive Supranuclear Palsy Emerging Therapies

13. Progressive Supranuclear Palsy Seven Major Market Analysis

14. Attribute Analysis

15. Progressive Supranuclear Palsy Market Outlook (7 major markets)

16. Progressive Supranuclear Palsy Access and Reimbursement Overview

17. KOL Views on the Progressive Supranuclear Palsy Market.

18. Progressive Supranuclear Palsy Market Drivers

19. Progressive Supranuclear Palsy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Oncolytic Virus Cancer Therapy Market

DelveInsight’s “Oncolytic Virus Cancer Therapy Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Oncolytic Virus Cancer Therapy Market size, share, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States